-

10:08:47 AM

DYN Stock News

DYN - Dyne Therapeutics Inc

06/01/23 7:30 AM

Nasdaq : DYN

conferences

Dyne Therapeutics to Present at Jefferies Healthcare Conference

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to

RHEA-AI

neutral

05/25/23 7:30 AM

Nasdaq : DYN

clinical trial

Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on

RHEA-AI

neutral

05/17/23 7:30 AM

Nasdaq : DYN

clinical trial

Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on

RHEA-AI

neutral

05/11/23 7:30 AM

Nasdaq : DYN

earnings

Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused

RHEA-AI

neutral

05/03/23 7:35 AM

Nasdaq : DYN

conferences

Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to

RHEA-AI

neutral

05/02/23 4:46 PM

Nasdaq : DYN

Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on

RHEA-AI

neutral

03/23/23 7:30 AM

Nasdaq : DYN

Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative

RHEA-AI

very positive

03/20/23 7:30 AM

Nasdaq : DYN

Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference

- Company Presents Overviews of ACHIEVE and DELIVER Global Clinical Trials with Data Anticipated from Both Studies in the Second Half of 2023 - - FORCE™ Platform Achieves Robust Exon Skipping, Restores Dystrophin at the Sarcolemma and Halts Progression of Fibrosis in a Severe In Vivo Model of

RHEA-AI

positive

03/07/23 7:30 AM

Nasdaq : DYN

conferences

Dyne Therapeutics to Present at Upcoming Investor Conferences

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to

RHEA-AI

neutral

03/02/23 7:30 AM

Nasdaq : DYN

earnings

Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing

RHEA-AI

neutral

1 2 3 4 5 6 Next

DYN Data

IndustryPharmaceutical Preparation Manufacturing
Websitedyne-tx.com
CeoJoshua T. Brumm
Security nameDyne Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Tags
- Commercial Services
- Miscellaneous Commercial Services
- Health Technology
- Biotechnology

About Dyne Therapeutics Inc

dyne therapeutics, inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the united states. it develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its force platform that delivers disease-modifying therapies. the company was founded in 2017 and is based in waltham, massachusetts.